π½π΄πππΎπ»π°π± π°πΈ πΈπ π±ππΈπ»π³πΈπ½πΆ π°πΈ π΅πΎπ π½π΄πππΎππ²πΈπ΄π½π²π΄ ππ΄ππ΄π°ππ²π·
Drug discovery is already difficult, drug discovery for the brain is even harder because researchers have to connect molecules, receptors, cells, neural pathways and brain regions before they can understand where a compound could be useful.
@NootropicsDAO_ is building a research agent that helps make those connections.
Hereβs what theyβre building, how it could be used in real research, and why the DeSci angle matters.
π§΅
Bio Africa retweeted
Enter the scientific singularity π§¬
Scientists building biotechs through networks of labs with AI helping coordinate the work.
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: Iβm here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
β¦and yes, it has gotten so boring around here that Iβm literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, βelsewhereβ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, Iβm grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithrilβs primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came βPipeline-in-a-Person.β The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropicβs acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo⦠but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and Iβm willing to bet theyβll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyoneβs earned a proper introduction, you all have.
Itβs difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope Iβve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isnβt going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
Bio Africa retweeted
He reveals deep and hidden things; he knows what lies in darkness, and light dwells with him. Daniel 2:22
Scientific singularity loading
Bio Africa retweeted
SRS and Eurospine, the classics, standed on same agenda this year. SpineDAO was there, Sydney and Gotenborg. While @VirginieLafage was holding the Australian gate, @BasselDiebo @GuillaumeLonjon and @CristiniJoseph5 illuminated Europe. So many little bit of something to come in next days. Stay tuned. Spine Care is about to change forever.
solana:spinezMPKxkBpf4Q9xET2587fehM3LuKe4xoAoXtSjR is on @solana, backed by @BioProtocol.
100% of the $NDT Ignition fundraising goal has been reached.
And now thereβs less than 30 minutes left before the Ignition presale closes.
The @NootropicsDAO_ community clearly came in stronger than expected, and the teamβs forecasting didnβt quite account for how bullish the community would be.
If youβve been watching NeuroLab and were waiting until the final stretch, this is the window.
Less than 30 minutes remain before the Ignition closes.
Join while itβs still open: app.bio.xyz/agents/neurolab-β¦
What comes next for NeuroLab?
The $NDT Ignition is only one step in a much bigger roadmap.
@NootropicsDAO_ is building toward a research platform that moves from AI-powered brain inference to deeper, more accessible and collaborative drug discovery.
β Platform Beta - structured evidence and inference reports.
β Genesis β Commons - expanding from open exploration into agent access, research workflows and community-led discovery.
The roadmap currently spans 7 major releases, 19 initiatives and 7 technical domains, with development planned across Q3 2026 to Q1 2027.
The goal is simple: make complex CNS drug discovery easier to explore, investigate and build on.
Here's a review on the Roadmap:
The $NDT Ignition is approaching its final stretch, but the bigger story is what comes after it.
@NootropicsDAO_ is building an AI-powered system for CNS drug discovery, using a large biomedical knowledge graph to connect compounds, receptors, cells, brain circuits and potential cognitive effects.
The Ignition gives the project an important starting point, but the roadmap is where the product begins to take shape.
β Atlas brings the knowledge graph into an interactive research environment
β Axon expands access through APIs and agent integrations
β Frontier moves toward novel structures, peptides and broader pharmacology
β Workbench gives researchers tools to build libraries, investigate compounds and develop hypotheses
β Cortex aims for deeper causal reasoning across the brain
β Commons brings researchers and the wider community into compound discovery and collaboration
So the next phase is not simply about $NDT, It's turning the infrastructure NeuroLab has been building into tools that researchers can actually use, test and validate.
That is the part worth watching after the Ignition.
Join the $NDT Ignition: app.bio.xyz/agents/neurolab-β¦
Bio Africa retweeted
Weβre live!
Come watch the NeuroLab demo, drop your questions in the chat, and letβs talk about what weβre building.
DeSciβs Drug Discovery OS. For the Human Brain.
teapawt.org/i/broadcasts/1qGoNYrmnβ¦
Bio Africa retweeted
48 hours left in the $NDT Ignition presale. 69K to go.
NeuroLab. DeSciβs Drug Discovery OS. For the Human Brain.
Backed by @bioprotocol, @beakerDAO, and scientists from Harvard and Stanford.
Watch the demo. Join the Ignition:
app.bio.xyz/agentsβ¦ teapawt.org/i/broadcasts/1qGoNYrmnβ¦
Bio Africa retweeted
π°π΅ππ΄π ππ·π΄ $π½π³π πΈπΆπ½πΈππΈπΎπ½ ππ°π»π΄, ππ·π°πβπ π½π΄ππ π΅πΎπ π½π΄πππΎπ»π°π±?
The $NDT Ignition Sale is now behind us
But for NeuroLab, this is where the next phase begins
The sale was about bringing the project into the Bio ecosystem and giving the wider community a way to participate.
Now the focus shifts to the part that matters most: building and validating the product
The next step is Atlas
NeuroLabβs roadmap starts with Atlas, planned for Q4 2026.
The goal is to make its research system easier to access, with a free user tier and interactive exploration of its biomedical knowledge graph.
In simple terms, users should be able to explore how compounds, targets and different parts of the brain are connected without having to manually piece everything together.
Then comes Axon and Frontier
Axon is focused on APIs, MCP access and integrations with other tools.
That could allow NeuroLab to become part of wider research workflows rather than existing as a standalone application.
Frontier takes the research side further, with plans for novel-structure and peptide inference, expanded pharmacology and stronger evidence tracking.
This is where NeuroLab starts moving deeper into the actual drug-discovery process.
2027 gets even more ambitious
The roadmap then moves into Workbench, which is designed around personal research libraries, saved data, compound groups and hypothesis development.
After that comes Cortex, focused on deeper causal reasoning and mapping across the brain at multiple levels.
And finally, Commons brings the DeSci vision closer to the research process itself, with plans for community compound submissions, prioritisation and shared IP frameworks.
So the Ignition Sale was not the destination
It was the funding and ecosystem milestone before the more important work begins.
Now NeuroLab has to turn the roadmap into working tools, validate the technology and show researchers why this infrastructure is useful.
That is the phase worth watching next
You can explore and get more details here: launch.neurolabai.io/?view=rβ¦
π°π΅ππ΄π ππ·π΄ $π½π³π πΈπΆπ½πΈππΈπΎπ½ ππ°π»π΄, ππ·π°πβπ π½π΄ππ π΅πΎπ π½π΄πππΎπ»π°π±?
The $NDT Ignition Sale is now behind us
But for NeuroLab, this is where the next phase begins
The sale was about bringing the project into the Bio ecosystem and giving the wider community a way to participate.
Now the focus shifts to the part that matters most: building and validating the product
The next step is Atlas
NeuroLabβs roadmap starts with Atlas, planned for Q4 2026.
The goal is to make its research system easier to access, with a free user tier and interactive exploration of its biomedical knowledge graph.
In simple terms, users should be able to explore how compounds, targets and different parts of the brain are connected without having to manually piece everything together.
Then comes Axon and Frontier
Axon is focused on APIs, MCP access and integrations with other tools.
That could allow NeuroLab to become part of wider research workflows rather than existing as a standalone application.
Frontier takes the research side further, with plans for novel-structure and peptide inference, expanded pharmacology and stronger evidence tracking.
This is where NeuroLab starts moving deeper into the actual drug-discovery process.
2027 gets even more ambitious
The roadmap then moves into Workbench, which is designed around personal research libraries, saved data, compound groups and hypothesis development.
After that comes Cortex, focused on deeper causal reasoning and mapping across the brain at multiple levels.
And finally, Commons brings the DeSci vision closer to the research process itself, with plans for community compound submissions, prioritisation and shared IP frameworks.
So the Ignition Sale was not the destination
It was the funding and ecosystem milestone before the more important work begins.
Now NeuroLab has to turn the roadmap into working tools, validate the technology and show researchers why this infrastructure is useful.
That is the phase worth watching next
You can explore and get more details here: launch.neurolabai.io/?view=rβ¦
Bio Africa retweeted
βScience is really the engine of progress for civilization but that engine is kind of stalled a little bit. What we really need is open and permissionless science.β
Science should be open to anyone who wants to help move it forward.
Thatβs the idea behind Bio: open research networks where scientists steer AI agents, share evidence others can build on, and work with communities to fund and develop the science they care about.
βScience is really the engine of progress for civilization but that engine is kind of stalled a little bit.β β @paulkhls, DeSci Lagos 2025
Last year, we explored what happens when we rethink how science is funded, developed and shared.
But the conversation doesn't end with discovery.
What happens next?
This year, we're taking that question further. We are exploring how research can move from paper to product, and from potential to real-world impact.
At DeSci Lagos 2026, the conversation continues.
Stay tuned π
Bio Africa retweeted
New Milestone cleared!
53k USD and growing!
25% in less than 2 days
12 days to go!
Thank you everyone that has supported us so far π€.
WAGMI
app.bio.xyz/agents/neurolab-β¦
The $NDT sale is now officialy LIVE π«‘
app.bio.xyz/agents/neurolab-β¦
Bio Africa retweeted
π½π΄πππΎπ»π°π± π°πΈ πΈπ π±ππΈπ»π³πΈπ½πΆ π°πΈ π΅πΎπ π½π΄πππΎππ²πΈπ΄π½π²π΄ ππ΄ππ΄π°ππ²π·
Drug discovery is already difficult, drug discovery for the brain is even harder because researchers have to connect molecules, receptors, cells, neural pathways and brain regions before they can understand where a compound could be useful.
@NootropicsDAO_ is building a research agent that helps make those connections.
Hereβs what theyβre building, how it could be used in real research, and why the DeSci angle matters.
π§΅
π΄ππΏπ»πΎππ΄ π½π΄πππΎπ»π°π±
NeuroLab is still early, but the direction is clear.
AI helps researchers analyse and connect complex biological information.
Biomedical data provides the scientific foundation
DeSci & Web3 supports a more open and collaborative research ecosystem.
The bigger goal is to make neuroscience research easier to explore, easier to connect and easier to build on.
Explore the project and see what theyβre building:
Launch Hub:
launch.neurolabai.io/
Bio Agent:
app.bio.xyz/agents
NeuroLab:
neurolabai.io/
ππ·π°π ππ΄π±3 π°π½π³ π³π΄ππ²πΈ π°π³π³ ππΎ πΈπ
This is where NeuroLab gets interesting from a Web3 perspective.
The project is being built within the Bio ecosystem and follows the broader DeSci idea of making scientific research more open and collaborative.
Its roadmap includes:
β Atlas β knowledge-graph exploration
β Axon β APIs and agent integrations
β Workbench β research libraries and hypothesis development
β Cortex β deeper whole-brain reasoning
β Commons β community compound submissions, research prioritisation and shared IP frameworks
So the Web3 side isn't simply about launching a token, it's more of building infrastructure around access, collaboration, contribution and ownership in scientific research.
That creates the possibility for researchers and communities to participate in the discovery process in new ways.
ππ·π΄ π·π΄π°π»ππ·π²π°ππ΄ π±π΄π½π΄π΅πΈπ
This is bigger than helping researchers work with molecules.
NeuroLab's materials cite an estimated 3.4 billion people, around 43% of the global population, living with a nervous-system condition.
That means improvements in neuroscience research could eventually affect a very large part of the world's population.
Better research tools could help scientists explore more hypotheses, investigate compounds faster and uncover biological relationships that might otherwise take much longer to find.
The important word is potential
NeuroLab still has to prove how well the technology performs through real scientific validation.
ππ·π π΄π°ππ»π-πππ°πΆπ΄ π³πΈππ²πΎπ
π΄ππ πΌπ°πππ΄ππ
A lot of potential drugs never make it through development.
NeuroLab's published materials cite a 6.2% clinical approval success rate for CNS compounds, compared with 13.3% for non-CNS compounds.
They also cite more than 90% of CNS candidates entering first-in-human trials failing.
That makes the early stages of research extremely important.
Tools that help researchers investigate mechanisms, compare possibilities and identify weaker directions earlier could potentially save time and resources throughout the discovery process.
